Pulmonary Hypertension: From Molecular Pathways to Patient Care.
E, N., GM, A., F, M., P, G., P, P.F., & S, P. (2026). Pulmonary Hypertension: From Molecular Pathways to Patient Care.. Heart failure clinics. https://doi.org/10.1016/j.hfc.2026.02.002
E N, GM A, F M, P G, P PF, S P. Pulmonary Hypertension: From Molecular Pathways to Patient Care.. Heart failure clinics. 2026; doi: 10.1016/j.hfc.2026.02.002
E N, GM A, F M, et al. Pulmonary Hypertension: From Molecular Pathways to Patient Care.[J]. Heart failure clinics. 2026. DOI: 10.1016/j.hfc.2026.02.002.
@article{e2026,
author = {Nardi E and Abbellito GM and Marzano F and Gargiulo P and Perrone-Filardi P and Paolillo S},
title = {Pulmonary Hypertension: From Molecular Pathways to Patient Care.},
journal = {Heart failure clinics},
year = {2026},
doi = {10.1016/j.hfc.2026.02.002},
note = {PMID: 42309621},
}
TY - JOUR AU - Nardi E AU - Abbellito GM AU - Marzano F AU - Gargiulo P AU - Perrone-Filardi P AU - Paolillo S TI - Pulmonary Hypertension: From Molecular Pathways to Patient Care. T2 - Heart failure clinics PY - 2026 DO - 10.1016/j.hfc.2026.02.002 AN - PMID:42309621 ER -
Pulmonary hypertension (PH) is a heterogeneous condition defined by an increase in mean pulmonary arterial pressure over 20 mm Hg diagnosed through right heart catheterization. Its global prevalence is around 0.6% to 1%. The prognosis used to be poor but nowadays early diagnosis, risk stratification, and a personalized treatment can significantly enhance the prognosis and quality of life of these patients. PH pathophysiology comprises genetic and environmental factors, such as endothelial dysfunction, smooth muscle cell proliferation, inflammation, thrombosis, and right ventricular remodeling. Especially in pulmonary arterial hypertension, treatment options have been radically altered.